TD Cowen lowered the firm’s price target on Cue Health to $5 from $7 and keeps an Outperform rating on the shares. The analyst said management gave 1Q guidance of $20M- $25M below our prior 1Q estimate of $56.4M as COVID testing continues to wave. Importantly menu expansion remains on track with approvals key to accelerate topline growth and unlock the long-term value/opportunity.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on HLTH: